Grifols (GRFS) Amortization of Deferred Charges (2010 - 2016)
Grifols' (GRFS) quarterly Amortization of Deferred Charges came in at $4.6 billion in Q4 2016, up 9.06% YoY from $4.3 billion in Q1 2016, and up 7253.3% on a QoQ basis from $63.2 million in Q3 2016.
Grifols (GRFS) Amortization of Deferred Charges (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Amortization of Deferred Charges data on file, last reported at $4.6 billion in Q4 2016.
- Quarterly Amortization of Deferred Charges rose 9.06% year-over-year to $4.6 billion in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.7 billion (up 4.56% YoY) and the FY2016 annual result came in at $4.8 billion, up 10.34% from the prior year.
- Amortization of Deferred Charges rose to $4.6 billion in Q4 2016, from $63.2 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $4.6 billion in Q4 2016 to a low of -$4.2 billion in Q2 2016.
- A 5-year average of $1.5 billion and a median of $1.6 billion in 2012 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2014 — Amortization of Deferred Charges jumped 638.69% — and 2016, when it sank 8932.49%.
- Tracing GRFS's Amortization of Deferred Charges over 5 years: stood at $2.9 billion in 2012, then advanced by 11.66% to $3.3 billion in 2013, then rose by 16.75% to $3.8 billion in 2014, then grew by 11.29% to $4.3 billion in 2015, then increased by 9.06% to $4.6 billion in 2016.
- The last three Amortization of Deferred Charges figures came in at $4.6 billion (Q4 2016), $63.2 million (Q3 2016), and -$4.2 billion (Q2 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 4.64 Bn |
| Dec 31, 2016 | 4.64 Bn |
| Sep 30, 2016 | 63.16 Mn |
| Sep 30, 2016 | 63.16 Mn |
| Jun 30, 2016 | -4.17 Bn |
| Jun 30, 2016 | -4.17 Bn |
| Mar 31, 2016 | 4.20 Bn |
| Mar 31, 2016 | 4.20 Bn |
| Dec 31, 2015 | 4.26 Bn |
| Dec 31, 2015 | 4.26 Bn |
| Sep 30, 2015 | -3.88 Bn |
| Sep 30, 2015 | -3.88 Bn |
| Jun 30, 2015 | -46.13 Mn |
| Jun 30, 2015 | -46.13 Mn |
| Mar 31, 2015 | 4.21 Bn |
| Mar 31, 2015 | 4.21 Bn |
| Dec 31, 2014 | 3.83 Bn |
| Dec 31, 2014 | 3.83 Bn |
| Sep 30, 2014 | 289.18 Mn |
| Sep 30, 2014 | 289.18 Mn |